BioCryst Pharmaceuticals Inc. (NASDAQ:BCRX) has a beta value of 2.67 and has seen 2,421,623 shares traded in the last trading session. The company, currently valued at $1.99 Billion, closed the last trade at $11.18 per share which meant it lost -$0.46 on the day or -3.91% during that session. The BCRX stock price is -27.37% off its 52-week high price of $14.24 and 82.92% above the 52-week low of $1.91. If we look at the company’s 10-day average daily trading volume, we find that it stood at 5.22 Million shares traded. The 3-month trading volume is 7.35 Million shares.
The consensus among analysts is that BioCryst Pharmaceuticals Inc. (BCRX) is a Buy stock at the moment, with a recommendation rating of 2. None of the analysts rate the stock as a Sell, while none rate it as Overweight. 2 out of 11 have rated it as a Hold, with 9 advising it as a Buy. None have rated the stock as Underweight. The expected earnings per share for the stock is -$0.27.
BioCryst Pharmaceuticals Inc. (NASDAQ:BCRX) trade information
Despite being -3.91% in the red in last session, the stock has traded in the green over the last five days, with the highest price hit on Tuesday, Apr 27 when the BCRX stock price touched $12.75- or saw a rise of 12.31%. Year-to-date, BioCryst Pharmaceuticals Inc. shares have moved 50.07%, while the 5-day performance has seen it change -9.73%. Over the past 30 days, the shares of BioCryst Pharmaceuticals Inc. (NASDAQ:BCRX) have changed 12.36%. Short interest in the company has seen 24.98 Million shares shorted with days to cover at 3.4.
Wall Street analysts have a consensus price target for the stock at $14.8, which means that the shares’ value could jump 32.38% from current levels. The projected low price target is $9 while the price target rests at a high of $19. In that case, then, we find that the current price level is +69.95% off the targeted high while a plunge would see the stock lose -19.5% from current levels.
BioCryst Pharmaceuticals Inc. (BCRX) estimates and forecasts
Figures show that BioCryst Pharmaceuticals Inc. shares have underperformed across the wider relevant industry. The company’s shares have gained +199.73% over the past 6 months, with this year growth rate of 5.5%, compared to 16.6% for the industry. Other than that, the company has, however, lowered its growth outlook for the 2021 fiscal year revenue. Growth estimates for the current quarter are -12.5% and -4.2% for the next quarter. Revenue growth from the last financial year stood is estimated to be +258.1%.
If we evaluate the company’s growth over the last 5-year and for the next 5-year period, we find that annual earnings growth was -13.1% over the past 5 years. Earnings growth for 2021 is a modest -16% while over the next 5 years, the company’s earnings are expected to increase by 19.9%.
BioCryst Pharmaceuticals Inc. (NASDAQ:BCRX)’s Major holders
Insiders own 0.87% of the company shares, while shares held by institutions stand at 68.63% with a share float percentage of 69.23%. Investors are also buoyed by the number of investors in a company, with BioCryst Pharmaceuticals Inc. having a total of 253 institutions that hold shares in the company. The top two institutional holders are Blackrock Inc. with over 16.26 Million shares worth more than $121.14 Million. As of December 30, 2020, Blackrock Inc. held 9.15% of shares outstanding.
The other major institutional holder is Baker Brothers Advisors, LLC, with the holding of over 12.7 Million shares as of December 30, 2020. The firm’s total holdings are worth over $94.58 Million and represent 7.15% of shares outstanding.
Also the top two Mutual Funds that are holding company’s shares are Vanguard Total Stock Market Index Fund and iShares Russell 2000 ETF. As of December 30, 2020, the former fund manager holds about 2.79% shares in the company for having 4949617 shares of worth $36.87 Million while later fund manager owns 4.33 Million shares of worth $44.07 Million as of March 30, 2021, which makes it owner of about 2.44% of company’s outstanding stock.